Vol. 63 No. 2 (2017), ORIGINAL ARTICLES. B. EXPERIMENTAL RESEARCH

Vol. 63 No. 2 (2017)

HARMONIZED STATISTICAL ANALYSIS OF THE EFFICACY OF INTRAPERITONEAL CHEMOTHERAPY REGIMENS WITH DIOXADET ON ASCITIC OVARIAN CANCER MODEL

ORIGINAL ARTICLES. B. EXPERIMENTAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-2-329-335

Published 01.02.2017

Vladimir Bespalov⁺⁻
Aleksey Belyaev⁺⁻
Denis Baranenko⁺⁻
Nikita Khromov-borisov⁺⁻
Valeriy Aleksandrov⁺⁻
Larisa Krasilnikova⁺⁻
Galina Kireeva⁺⁻
Olesya Belyaeva⁺⁻
Konstantin Senchik⁺⁻
Aleksandr Stukov⁺⁻
Irina Vasileva⁺⁻
Aleksandr Semenov⁺⁻
Grigoriy Tochilnikov⁺⁻
Ivan Alvovskiy⁺⁻
Ye. Vyshinskaya⁺⁻

Vladimir Bespalov

N.N. Petrov Research Institute of Oncology, ITMO University

Aleksey Belyaev

N.N. Petrov Research Institute of Oncology, I.I. Mechnikov North-West State Medical University

Denis Baranenko

ITMO University

Nikita Khromov-borisov

R.R. Vreden Russian Scientific Research Institute of Traumatology and Orthopedics

Valeriy Aleksandrov

N.N. Petrov Research Institute of Oncology, ITMO University

Larisa Krasilnikova

N.N. Petrov Research Institute of Oncology

Galina Kireeva

N.N. Petrov Research Institute of Oncology

Olesya Belyaeva

N.N. Petrov Research Institute of Oncology

Konstantin Senchik

N.N. Petrov Research Institute of Oncology

Aleksandr Stukov

N.N. Petrov Research Institute of Oncology

Irina Vasileva

N.N. Petrov Research Institute of Oncology, ITMO University

Aleksandr Semenov

N.N. Petrov Research Institute of Oncology, ITMO University

Grigoriy Tochilnikov

N.N. Petrov Research Institute of Oncology, ITMO University

Ivan Alvovskiy

N.N. Petrov Research Institute of Oncology, ITMO University

Ye. Vyshinskaya

N.N. Petrov Research Institute of Oncology

PDF (Русский)

Keywords

INTRAPERITONEAL CHEMOTHERAPY
NORMOTHERMIC AND HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION
OVARIAN CANCER
DIOXADET

How to Cite

Bespalov, V., Belyaev, A., Baranenko, D., Khromov-borisov, N., Aleksandrov, V., Krasilnikova, L., Kireeva, G., Belyaeva, O., Senchik, K., Stukov, A., Vasileva, I., Semenov, A., Tochilnikov, G., Alvovskiy, I., & Vyshinskaya, Y. (2017). HARMONIZED STATISTICAL ANALYSIS OF THE EFFICACY OF INTRAPERITONEAL CHEMOTHERAPY REGIMENS WITH DIOXADET ON ASCITIC OVARIAN CANCER MODEL. Voprosy Onkologii, 63(2), 329–335. https://doi.org/10.37469/0507-3758-2017-63-2-329-335

Abstract

A comparative statistical study of the results of eight independent experiments on the efficacy of intraperitoneal chemotherapy has been performed. The regiments of cathether intraperitoneal chemotherapy (CIPC), normothermic and hyperthermic chemoperfusion (NIPEC and HIPEC) with antitumor drug dioxadet were investigated in 288 female Wistar rats with ascitic ovarian cancer. Ovarian cancer was transplanted intra-peritoneally (i.p.) 48 hours prior to a single chemotherapy at a number of 1*107 tumor cells. Dioxadet was administered at the maximum tolerated doses: CIPC - via syringe - 1.5 mg/kg body weight; NIPEC (36,5-37,5°С) and HIPEC (40,5-41,5°С) - infused for a continuous circulation using an experimental setting - at respective doses 30 and 15 mg/kg body weight. The rats in the control groups were administered in the same manner with physiological saline solution. The antitumor effects of the treatment were estimated as an increase in survival time. The statistical analysis was based on the principles of harmonization of statistical evidence and predictions. The mean survival time in the control group without treatment (i.p. saline injection) was 15 days with 95% confidence interval (CI) from 12 to 19 days. IPC, NIPEC and HIPEC increased mean survival time by 85, 97 and 202% (p<0.001 for the all cases) compared to the control group without treatment. Thus, HIPEC is the most effective mode of i.p. chemotherapy with antitumor drug dioxadet.

https://doi.org/10.37469/0507-3758-2017-63-2-329-335

PDF (Русский)

References

Беляева О.А., Беспалов В.Г., Сенчик К.Ю. и др. Химиоперфузионное лечение канцероматоза брюшной полости. - СПб., 2016. - 146 с.

Беспалов В.Г., Вышинская Е.А., Васильева И.Н. и др. Интраперитонеальная химиотерапия - путь повышения эффективности лечения рака яичника // Вопр. онкол. - 2015. - Т. 61. - № 4. - C. 634-641.

Беспалов В.Г., Киреева Г.С., Беляева О.А. и др. Интраоперационное внутрибрюшинное химиоперфузионное лечение цисплатином и диоксадэтом на модели канцероматоза брюшной полости при раке яичника: оценка безопасности и эффективности // Вопр. онкол. - 2015. - Т. 61. - № 4. - C. 647-652.

Вышинская Е.А., Беспалов В.Г., Васильева И.Н. и др. Преимущества интраперитонеальной химиотерапии в лечении канцероматоза брюшной полости при раке яичника // Ж. акуш. и жен. болезн. - 2014. - Т. 63. -№ 2. - С. 28-34.

Гершанович М.Л., Филов В.А., Котова Д.Г. и др. Результаты кооперированного клинического изучения противоопухолевого препарата диоксадэт по II фазе // Вопр. онкол. - 1998. - T.44. - № 2. - С. 216-220.

Стуков А.Н., Гершанович М.Л., Беспалов В.Г. и др. Классификация противоопухолевых препаратов // Медлайн-Экспресс. - 2012. - № 2. - C. 20-24.

Хромов-Борисов Н.Н. Гармонизация статистических доказательств и предсказаний в биомедицине // I Открытый российский статистический конгресс: Сборник докладов. - Новосибирск: НГУЭУ, 2016. - C. 39-53.

Ansaloni L., Coccolini F., Morosi L. et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer // Br. J. Cancer. - 2015. - Vol. 112. - P. 306-312.

Bespalov V.G., Kireeva G.S., Belyaeva O.A. et al. Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model // J. Surg. Oncol. - 2016. -Vol. 113. - P. 438-442.

Bespalov V.G., Kireeva G.S., Belyaeva O.A. et al. Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer // J. Chemother. - 2016. - Vol. 28. - P. 203-209.

Boisen M.M., Richard S.D., Holtzman M.P. et al. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role? // J. Gastrointest. Oncol. - 2016. - Vol. 7. - P. 10-17.

Bookman M.A. Optimal primary therapy of ovarian cancer // Ann. Oncol. - 2016. - Suppl. 1. - P. 58-62.

Chan D.L., Morris D.L., Rao A., Chua T.C. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy // Cancer Manag. Res. - 2012. - Vol. 4. - P. 413-422.

Faul F., Erdfelder E., Buchner A., Lang A.G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses // Behav. Res. Methods. - Vol. 41. - P. 1149-1160.

Ferlay J., Soerjomataram I., Ervik M. et al. GLOBOCAN 2012 v. 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base № 11. Электронный ресурс. URL: http://glo-bocan.iarc.fr/Default.aspx (дата обращения: 13.07.2016).

Gourley C., Walker J.L., Mackay H.J. Update on intraperi-toneal chemotherapy for the treatment of epithelial ovarian cancer // Am. Soc. Clin. Oncol. Educ. Book. - 2016. - Vol. 35. - P. 143-151.

Grosso G., Rossetti D., Coccolini F. et al. Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey // Arch. Gynecol. Obstet. - 2014. - Vol. 290. - P. 425-422.

Hammer 0., Harper D., Ryan P. PAST: paleontological statistics software package for education and data analysis // Palaeontol. Electron. - 2001. - Vol. 4. - P. 4-9.

ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. - 2015. Электронный ресурс. URL: http:// www.icmje.org/recommendations

Jaaback K., Johnson N., Lawrie T.A. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer // Cochrane Database Syst. Rev. - 2016. - 1:CD005340.

Love J., Selker R., Marsman M. et al. «JASP» Computer software. - Version 0.6.6. - 2015.

Narod S. Can advanced-stage ovarian cancer be cured? // Nat. Rev. Clin. Oncol. - 2016. - Vol. 13. -P. 255-261.

Polom K., Roviello G., Generali D. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer // Int. J. Hyperthermia. -2016. - Vol. 32. - P. 298-310.

Wasserstein R.L., Lazar N.A. The ASA>s Statement on p-Values: Context, Process, and Purpose // Am. Stat. -2016. - Vol. 70. - P. 129-133.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.